Horizon Investment Services LLC Sells 23,707 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Horizon Investment Services LLC reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 83.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,759 shares of the biopharmaceutical company's stock after selling 23,707 shares during the quarter. Horizon Investment Services LLC's holdings in Halozyme Therapeutics were worth $228,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of HALO. CBIZ Investment Advisory Services LLC purchased a new position in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics in the 4th quarter worth about $29,000. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics during the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 322 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HALO has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Benchmark restated a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Remove Ads

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.58 during trading hours on Wednesday, reaching $62.45. 427,159 shares of the company traded hands, compared to its average volume of 1,377,177. The firm has a 50-day moving average price of $59.34 and a 200 day moving average price of $54.84. The company has a market cap of $7.71 billion, a P/E ratio of 18.21, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of the firm's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now directly owns 33,108 shares of the company's stock, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,200 shares of company stock valued at $1,786,668 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.